Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
ESC Heart Fail. 2021 Jun;8(3):2025-2035. doi: 10.1002/ehf2.13281. Epub 2021 Mar 11.
There are limited contemporary data on the use of initial fibrinolysis in ST-segment elevation myocardial infarction cardiogenic shock (STEMI-CS). This study sought to compare the outcomes of STEMI-CS receiving initial fibrinolysis vs. primary percutaneous coronary intervention (PPCI).
Using the National (Nationwide) Inpatient Sample from 2009 to 2017, a comparative effectiveness study of adult (>18 years) STEMI-CS admissions receiving pre-hospital/in-hospital fibrinolysis were compared with those receiving PPCI. Admissions with alternate indications for fibrinolysis and STEMI-CS managed medically or with surgical revascularization (without fibrinolysis) were excluded. Outcomes of interest included in-hospital mortality, development of non-cardiac organ failure, complications, hospital length of stay, hospitalization costs, use of palliative care, and do-not-resuscitate status.
During 2009-2017, 5297 and 110 452 admissions received initial fibrinolysis and PPCI, respectively. Compared with those receiving PPCI, the fibrinolysis group was more often non-White, with lower co-morbidity, and admitted on weekends and to small rural hospitals (all P < 0.001). In the fibrinolysis group, 95.3%, 77.4%, and 15.7% received angiography, PCI, and coronary artery bypass grafting, respectively. The fibrinolysis group had higher rates of haemorrhagic complications (13.5% vs. 9.9%; P < 0.001). The fibrinolysis group had comparable all-cause in-hospital mortality [logistic regression analysis: 28.8% vs. 28.5%; propensity-matched analysis: 30.8% vs. 30.3%; adjusted odds ratio 0.97 (95% confidence interval 0.90-1.05); P = 0.50]. The fibrinolysis group had comparable rates of acute organ failure, hospital length of stay, rates of palliative care referrals, do-not-resuscitate status use, and lesser hospitalization costs.
The use of initial fibrinolysis had comparable in-hospital mortality than those receiving PPCI in STEMI-CS in the contemporary era in this large national observational study.
目前关于 ST 段抬高型心肌梗死合并心原性休克(STEMI-CS)患者初始溶栓治疗的应用数据较为有限。本研究旨在比较 STEMI-CS 患者接受初始溶栓治疗与直接经皮冠状动脉介入治疗(PPCI)的结局。
利用 2009 年至 2017 年全国住院患者样本,对接受院前/院内溶栓治疗的成人(>18 岁)STEMI-CS 入院患者进行了一项比较效果的研究,并与接受 PPCI 的患者进行了比较。排除因其他适应证接受溶栓治疗且 STEMI-CS 接受药物治疗或手术血运重建(未接受溶栓治疗)的患者。主要观察终点包括院内死亡率、非心源性器官衰竭的发生、并发症、住院时间、住院费用、姑息治疗的使用和不复苏状态。
2009 年至 2017 年期间,分别有 5297 例和 110452 例患者接受初始溶栓治疗和 PPCI。与接受 PPCI 的患者相比,溶栓组患者更常见于非白人、合并症更少,且就诊于周末和小的农村医院(均 P<0.001)。在溶栓组中,95.3%、77.4%和 15.7%的患者分别接受了血管造影、经皮冠状动脉介入治疗和冠状动脉旁路移植术。溶栓组的出血性并发症发生率较高(13.5%比 9.9%;P<0.001)。溶栓组的全因院内死亡率相当[logistic 回归分析:28.8%比 28.5%;倾向评分匹配分析:30.8%比 30.3%;调整后的比值比 0.97(95%置信区间 0.90-1.05);P=0.50]。溶栓组的急性器官衰竭发生率、住院时间、姑息治疗转介率、不复苏状态使用率和住院费用均相当。
在这项大型全国性观察性研究中,与直接 PPCI 相比,在当代,STEMI-CS 患者接受初始溶栓治疗的院内死亡率相当。